Ivabradine Sandoz

Ivabradine, the active ingredient in Ivabradine Sandoz, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate adult patients.

GNH USA supplies Ivabradine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Ivabradine is used to manage conditions where reduction of heart rate improves clinical outcomes, primarily within the cardiovascular disease spectrum.

- Chronic stable angina pectoris: lowers heart rate to reduce the frequency of angina episodes and improve exercise tolerance. - Heart failure with reduced ejection fraction (NYHA class II–III): decreases heart rate, which can improve symptoms and reduce the risk of hospitalization.

Ivabradine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: resting heart rate below 50 bpm. - Headache. - Dizziness or light‑headedness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other significant arrhythmias. - Severe hypotension. - Persistent visual impairment. - Allergic reactions such as rash or angioedema.

When prescribing Ivabradine, clinicians should consider several safety and monitoring measures to minimize risk.

- Heart rate monitoring: obtain baseline resting heart rate and ensure it remains above 60 bpm before initiation. - Concomitant bradycardic agents: avoid or adjust dose when used with beta‑blockers, digoxin, or calcium‑channel blockers. - Severe hepatic impairment: use with caution or avoid as drug exposure may increase. - Pregnancy and lactation: safety not established; prescribe only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Ivabradine can interact with other medicines, altering its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Ivabradine exposure. - Other heart‑rate‑lowering drugs (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive bradycardia. - Certain anti‑arrhythmic agents (e.g., amiodarone): additive effect on cardiac conduction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents: monitor blood pressure and heart rate. - Diuretics: watch for electrolyte disturbances that could affect cardiac rhythm.